Skip to main content
Publish date:

Study Data Lift Sangamo

The stock is up 7% in early trading.

Sangamo BioSciences

(SGMO) - Get Sangamo Therapeutics, Inc. Report

was higher after the company said its technology might be capable of rendering human immune-system cells permanently resistant to HIV infection.

The company said after the close Wednesday that the resistance can be achieved by using what are called zinc finger DNA-binding protein nucleases, or ZFN's.

TheStreet Recommends

Sangamo's ZFNs are designed to permanently modify the DNA sequence encoding CCR5, a co-receptor that enables HIV to enter and infect immune-system cells.

Shares of Sangamo were gaining 40 cents, or 7.4%, to $5.78.

The company presented the data at a conference in San Francisco.